COMMUNIQUÉS West-GlobeNewswire

-
Replimune to Present at Upcoming Investor Conferences
30/05/2019 -
Rhythm Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
30/05/2019 -
Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference
30/05/2019 -
Neos Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
30/05/2019 -
Gritstone Oncology to Host Event with Oncology Key Opinion Leaders Discussing Neoantigen-based Immunotherapy During ASCO Annual Meeting
30/05/2019 -
Immuron Announces the Closing of Public Offering of ADSs
30/05/2019 -
Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference
30/05/2019 -
Daxor Corporation Announces New Partnership with Leading Hospital in North Carolina to Integrate the BVA-100® Blood Volume Analyzer Diagnostic Test as Part of Standard Clinical Practice
30/05/2019 -
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
30/05/2019 -
CorVel Announces Revenues and Earnings
30/05/2019 -
So-Young Reports First Quarter 2019 Unaudited Financial Results
30/05/2019 -
Tempus Announces $200 Million in Series F Financing
30/05/2019 -
Mesoblast Financial Results Webcast for Period Ended March 31, 2019
30/05/2019 -
Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
30/05/2019 -
Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)
30/05/2019 -
Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
30/05/2019 -
BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
30/05/2019 -
Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease
30/05/2019 -
Helix BioPharma Corp. Closes Private Placement
30/05/2019
Pages